A US study released on Tuesday revealed a cheap, three-ingredient injection cocktail administered by paramedics was able to reduce heart attack patients' risk of dying by 50 percent.
When the shot was given early to patients with signs of a heart attack, the mixture of glucose, insulin and potassium, or GIK, showed remarkable success in preventing full cardiac arrest -- when the heart stops beating -- and even death.
And each shot cocktail costs only about $50, according to the research presented at the American College of Cardiology's 61st annual scientific meeting in Chicago.
"Because the trial is the first to show GIK is effective when used by paramedics in real-world community settings, it could have important implications for the treatment of heart attacks," added Selker, executive director of the Institute for Clinical Research at Tufts Medical Center.
Previous trials using the formula were inconclusive, possibly because the shot was being given to patients too late, he said.
But this trial, which randomized 911 patients to receive either the shot or a placebo and was carried out by trained paramedics in 13 cities across the United States, showed positive effects in those who were given the treatment.
The treatment did not prevent heart attacks from occurring, but cut the likelihood of cardiac arrest by 50 percent over patients who did not get the shot. The risk of immediate death also dropped by 50 percent.
The effects were visible over the month following the event as well, with patients given the shot 40 percent less likely to die or be hospitalized for heart failure than those who did not.
In patients with a certain kind of heart attack in which a coronary artery becomes completely blocked, known as an ST-elevation heart attack, immediate GIK was associated with a 60 percent reduction in cardiac arrest or death.
Those who got GIK and were later confirmed to have had a heart attack saw an average of two percent of their heart tissue damaged, compared to 10 percent in the placebo group.
While 23 percent of the suspected heart attacks in the study turned out to be false alarms, patients who got the GIK shot showed no negative side effects from the treatment.
The key difference in this trial compared to previous ones appeared to be the act of giving the shot right away, rather than waiting for a confirmed diagnosis at the hospital.
"We wanted to do something that is effective and can be used anywhere," said Selker.
"More people die of heart attacks outside the hospital than inside the hospital. Hundreds of thousands of people per year are dying out in the community; we wanted to direct our attention to those patients."
For now, the treatment is not widely available. Further research is planned to track the study participants over the next year and evaluate its longer-term effects and benefits.